Functional selectivity through protean and biased agonism: who steers the ship?
- PMID: 17901198
- DOI: 10.1124/mol.107.040352
Functional selectivity through protean and biased agonism: who steers the ship?
Abstract
This article describes functional selectivity of agonists and antagonists and distinguishes conventional cell-based functional selectivity, where the strength of signal produces selective signaling in various organs, from true receptor active-state based selectivity, also alternatively referred to in the literature as "stimulus trafficking," "biased agonism," and "collateral efficacy." This latter mechanism of selectivity depends on the ligand-related conformation of the receptor and is not compatible with the parsimonious view that agonists produce a single receptor active state. In addition, protean agonism is described, whereby a ligand produces positive agonism in quiescent systems and inverse agonism in constitutively active systems. This is a special case of active state-based selectivity in which the ligand produces an active state that is of lower efficacy than the natural constitutively active state. It is postulated that receptor active-state based selectivity, unlike cell-based functional selectivity, is controllable through the chemical structure of the ligand and is therefore more likely to be a viable avenue for therapeutic selectivity in the clinic. Reasons are given for differentiating receptor active-state based selectivity from conventional functional organ selectivity.
Similar articles
-
The evasive nature of drug efficacy: implications for drug discovery.Trends Pharmacol Sci. 2007 Aug;28(8):423-30. doi: 10.1016/j.tips.2007.06.005. Epub 2007 Jul 19. Trends Pharmacol Sci. 2007. PMID: 17659355 Review.
-
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.Trends Pharmacol Sci. 2007 Aug;28(8):407-15. doi: 10.1016/j.tips.2007.06.009. Epub 2007 Jul 13. Trends Pharmacol Sci. 2007. PMID: 17629960 Review.
-
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.Mol Pharmacol. 2004 Jan;65(1):2-11. doi: 10.1124/mol.65.1.2. Mol Pharmacol. 2004. PMID: 14722230 Review.
-
The role of conformational ensembles of seven transmembrane receptors in functional selectivity.Curr Opin Pharmacol. 2010 Dec;10(6):775-81. doi: 10.1016/j.coph.2010.09.004. Curr Opin Pharmacol. 2010. PMID: 20933468 Review.
-
Molecular basis of inverse agonism in a G protein-coupled receptor.Nat Chem Biol. 2005 Jun;1(1):25-8. doi: 10.1038/nchembio705. Epub 2005 May 24. Nat Chem Biol. 2005. PMID: 16407989
Cited by
-
Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations.Mol Pharmacol. 2012 Jun;81(6):820-31. doi: 10.1124/mol.111.075457. Epub 2012 Mar 13. Mol Pharmacol. 2012. PMID: 22416052 Free PMC article.
-
Informatic deconvolution of biased GPCR signaling mechanisms from in vivo pharmacological experimentation.Methods. 2016 Jan 1;92:51-63. doi: 10.1016/j.ymeth.2015.05.013. Epub 2015 May 16. Methods. 2016. PMID: 25986936 Free PMC article.
-
Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.J Biol Chem. 2016 Oct 21;291(43):22460-22471. doi: 10.1074/jbc.M116.733220. Epub 2016 Sep 6. J Biol Chem. 2016. PMID: 27601473 Free PMC article.
-
G-protein-coupled receptor structure: what can we learn?F1000 Biol Rep. 2009 Feb 24;1:11. doi: 10.3410/B1-11. F1000 Biol Rep. 2009. PMID: 20948675 Free PMC article.
-
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.Neuropharmacology. 2011 Jan;60(1):66-81. doi: 10.1016/j.neuropharm.2010.07.007. Epub 2010 Jul 14. Neuropharmacology. 2011. PMID: 20637216 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
